Patheon signs strategic alliance agreement with Kemwell



    Expanding Capabilities to India

    ZUG, Switzerland, April 1 /CNW/ - Patheon (TSX:PTI), a global provider of
drug development and manufacturing services to the international
pharmaceutical industry today announced it has entered into a strategic
alliance agreement with Kemwell Pvt. Limited, a leading provider of
formulations contract manufacturing and development services based in
Bangalore, India.
    The alliance allows Patheon and Kemwell to refer and market each others'
services to clients to better meet their respective client's requirements. The
alliance is effective immediately and full promotion by Patheon's business
development units is expected by mid-year.
    "This alliance gives us more flexibility in our service offering. With
Kemwell's GMP facility and expertise, we can offer our clients low volume, low
cost solutions in solid, semi-solid and liquid dosage form manufacturing, and
a full range of formulation and CMC-related development services from a new
base in India," said Wes Wheeler, Chief Executive Officer and President of
Patheon Inc.
    "Patheon's aseptic and high-potent manufacturing expertise brings an
important capability to Kemwell's portfolio of services," said Anurag Bagaria,
Vice-President Business Development of Kemwell Pvt. Ltd. "We look forward to
actively and cooperatively meeting and exceeding our respective client's
requirements".

    ABOUT KEMWELL

    Bangalore-based Kemwell Pvt. Ltd. (www.kemwellpharma.com) is a leading
provider of formulations contract manufacturing and development services for
multinational pharmaceutical companies for over 20 years. From facilities in
India and Sweden, Kemwell manufactures tablets, capsules, liquid orals,
external drops, ointments, gels and creams. Kemwell's customers include 5 of
the top 10 pharmaceutical companies in the world, manufacturing 5 of the top
10 brands in India. Kemwell's Pharmaceutical Development Unit provides
services in clinical manufacturing and packaging, formulation and analytical
development, stability studies, regulatory documentation etc. With a 100%
commitment to pure play contract manufacturing, Kemwell has no branded
products of its own in the market, thereby avoiding any conflict of interests
with its customers.

    ABOUT PATHEON

    Patheon Inc. (TSX:PTI; www.patheon.com) is a leading global provider of
contract development and manufacturing services to the global pharmaceutical
industry. Patheon prides itself in providing the highest quality products and
services to more than 300 of the world's leading pharmaceutical and
biotechnology companies. Patheon's services range from preclinical development
through commercial manufacturing of a full array of dosage forms including
parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative
technologies including single-use disposables, liquid-filled hard capsules and
a variety of modified release technologies. Patheon's comprehensive range of
fully integrated Pharmaceutical Development Services includes pre-formulation,
formulation, analytical development, clinical manufacturing, scale-up and
commercialization. Patheon can take customers direct to clinic with global
clinical packaging and distribution services and Patheon's Quick to Clinic(TM)
programs can accelerate early phase development project to clinical trials
while minimizing the consumption of valuable API. Patheon's integrated
development and manufacturing network of 10 facilities, and 6 development
centers across North America and Europe, strives to ensure that customer
products can be launched with confidence anywhere in the world.

    Caution Concerning Forward-Looking Statements

    This news release may contain forward-looking statements which reflect
management's expectations regarding the Company's future growth of operations,
performance (both operational and financial) and business prospects and
opportunities. These statements are made in the context of the risks and
uncertainties that are outlined in the Company's public documents, which can
be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com.

    %SEDAR: 00001700E




For further information:

For further information: Mr. Wes Wheeler, President & Chief Executive
Officer, Tel: (919) 226-3200, Email: wes.wheeler@patheon.com; Mr. Eric Evans,
Chief Financial Officer, Tel: (919) 226-3204, Email: eric.evans@patheon.com;
Ms. Jean Treadwell, Investor Relations, Tel: (905) 816-8344, Email:
jean.treadwell@patheon.com; Mr. Anurag Bagaria, VP, Business Development,
Kemwell, Tel: +91-80-3928-6200, Email: anurag.bagaria@kemwellpharma.com

Organization Profile

Patheon Inc

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890